Table 3.
Test substance | Treatment | Min–max SCE | SCE/cell ± SE | M1 | M2 | M3 | RI ± SE | MI ± SE (%) | |
---|---|---|---|---|---|---|---|---|---|
Period (h) | Dose (μg mL−1) | ||||||||
Control | 24 | 0.00 | 1–8 | 4.36 ± 0.26 | 33 | 50 | 117 | 2.42 ± 0.05 | 11.00 ± 0.41 |
MMC | 24 | 0.2 | 20–56 | 38.30 ± 1.30 | 82 | 68 | 50 | 0.74 ± 0.09 | 5.00 ± 0.49 |
Acephate | 24 | 12.5 | 6–13 | 4.64 ± 0.27 | 41 | 41 | 118 | 1.77 ± 0.07 | 10.35 ± 0.68 |
25 | 4–19 | 5.60 ± 0.32 | 40 | 48 | 112 | 2.36 ± 0.05 | 9.75 ± 0.66 | ||
50 | 5–17 | 10.38 ± 0.56† | 32 | 42 | 126 | 2.47 ± 0.04 | 8.50 ± 0.62** | ||
100 | 6–18 | 11.60 ± 0.50† | 34 | 43 | 123 | 2.44 ± 0.04 | 7.65 ± 0.59*** | ||
200 | 8–19 | 12.00 ± 0.39† | 21 | 33 | 146 | 2.62 ± 0.05 | 6.55 ± 0.55*** | ||
Control | 48 | 0.00 | 2–7 | 3.64 ± 0.24 | 18 | 64 | 128 | 2.48 ± 0.05 | 11.93 ± 0.72 |
MMC | 48 | 0.2 | 25–83 | 54.32 ± 2.36 | 104 | 50 | 46 | 1.71 ± 0.06 | 4.00 ± 0.44 |
Acephate | 48 | 12.5 | 2–19 | 4.90 ± 0.29 | 45 | 52 | 103 | 2.30 ± 0.05 | 10.35 ± 0.68 |
25 | 2–13 | 7.42 ± 0.37† | 31 | 85 | 84 | 2.26 ± 0.05 | 9.50 ± 0.65* | ||
50 | 7–14 | 9.74 ± 0.34† | 35 | 77 | 89 | 2.80 ± 0.06 | 8.00 ± 0.61*** | ||
100 | 6–19 | 11.20 ± 0.60† | 25 | 47 | 128 | 2.51 ± 0.03 | 7.15 ± 0.58*** | ||
200 | 8–22 | 12.58 ± 0.44† | 32 | 49 | 119 | 2.68 ± 0.04 | 6.15 ± 0.54*** |
50 metaphases were scored for each concentration in SCE
200 metaphases were scored for each treatment in RI
2,000 metaphases were scored for each treatment in MI
† Significantly different from the control p < 0.05 (t-test)
* Significantly different from the control p < 0.05 (z-test)
** Significantly different from the control p < 0.01 (z-test)
*** Significantly different from the control p < 0.001 (z-test)